These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8149673)

  • 1. Oral and aerosol immunization with viable or inactivated Actinobacillus pleuropneumoniae bacteria: antibody response to capsular polysaccharides in bronchoalveolar lavage fluids (BALF) and sera of pigs.
    Hensel A; Pabst R; Bunka S; Petzoldt K
    Clin Exp Immunol; 1994 Apr; 96(1):91-7. PubMed ID: 8149673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral immunization of pigs with viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces pulmonary and systemic antibodies and protects against homologous aerosol challenge.
    Hensel A; Stockhofe-Zurwieden N; Petzoldt K; Lubitz W
    Infect Immun; 1995 Aug; 63(8):3048-53. PubMed ID: 7622229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aerosol exposure of pigs to viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces antibodies in bronchoalveolar lining fluids and serum, and protects against homologous challenge.
    Hensel A; Stockhofe-Zurwieden N; Ganter M; Petzoldt K
    Vet Microbiol; 1995 Nov; 47(1-2):27-41. PubMed ID: 8604553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state.
    Hensel A; Huter V; Katinger A; Raza P; Strnistschie C; Roesler U; Brand E; Lubitz W
    Vaccine; 2000 Jul; 18(26):2945-55. PubMed ID: 10825595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses.
    Katinger A; Lubitz W; Szostak MP; Stadler M; Klein R; Indra A; Huter V; Hensel A
    J Biotechnol; 1999 Aug; 73(2-3):251-60. PubMed ID: 10486934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective immunity following immunisation of pigs with aerosol of Actinobacillus pleuropneumoniae serotype 2.
    Loftager MK; Eriksen L; Aasted B; Nielsen R
    Res Vet Sci; 1993 Nov; 55(3):281-6. PubMed ID: 8284489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular changes in the bronchoalveolar lavage (BAL) of pigs, following immunization by the enteral or respiratory route.
    Delventhal S; Hensel A; Petzoldt K; Pabst R
    Clin Exp Immunol; 1992 Nov; 90(2):223-7. PubMed ID: 1424278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocyte subsets in bronchoalveolar lavage after exposure to Actinobacillus pleuropneumoniae in pigs previously immunized orally or by aerosol.
    Pabst R; Delventhal S; Gebert A; Hensel A; Petzoldt K
    Lung; 1995; 173(4):233-41. PubMed ID: 7564482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral immunization with lung-pathogenic bacteria is protective against defined challenge in a pig aerosol infection model.
    Hensel A; Delventhal S; Windt H; Stockhofe-Zurwieden N; Pabst R; Petzoldt K
    Adv Exp Med Biol; 1995; 371B():803-6. PubMed ID: 7502901
    [No Abstract]   [Full Text] [Related]  

  • 10. Protective local and systemic antibody responses of swine exposed to an aerosol of Actinobacillus pleuropneumoniae serotype 1.
    Bossé JT; Johnson RP; Nemec M; Rosendal S
    Infect Immun; 1992 Feb; 60(2):479-84. PubMed ID: 1730479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosol treatment of pigs with Actinobacillus pleuropneumoniae serotype 2: mucosal immunity and resistance against challenge.
    Loftager MK; Eriksen L; Nielsen R
    Adv Exp Med Biol; 1995; 371B():1611-4. PubMed ID: 7502867
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic and local antibody responses after experimental infection with Actinobacillus pleuropneumoniae in piglets with passive or active immunity.
    Krejci J; Nechvatalova K; Kudlackova H; Faldyna M; Kucerova Z; Toman M
    J Vet Med B Infect Dis Vet Public Health; 2005 May; 52(4):190-6. PubMed ID: 16000115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization by the enteral and respiratory route with viable and inactivated bacteria results in a differential increase in lymphocyte subsets in the bronchoalveolar space.
    Pabst R; Delventhal S; Hensel A; Petzoldt K
    Adv Exp Med Biol; 1995; 371B():1459-61. PubMed ID: 7502837
    [No Abstract]   [Full Text] [Related]  

  • 14. Downregulation of a protective Actinobacillus pleuropneumoniae antigen during the course of infection.
    Hennig I; Teutenberg-Riedel B; Gerlach GF
    Microb Pathog; 1999 Feb; 26(2):53-63. PubMed ID: 10090852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance of Actinobacillus pleuropneumoniae to bactericidal antibody and complement is mediated by capsular polysaccharide and blocking antibody specific for lipopolysaccharide.
    Ward CK; Inzana TJ
    J Immunol; 1994 Sep; 153(5):2110-21. PubMed ID: 8051416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The appearance of specific IgG and IgA antibodies to Streptococcus pneumoniae in serum and lung lavage fluid of mice after the administration of different antigens. 2. IgG and IgA antibody detection after intraperitoneal, aerosol and oral immunization with Streptococcus pneumoniae].
    Schumann V; Tischner H; Noack K; Schröder R; Pohl WD
    Z Erkr Atmungsorgane; 1988; 171(1):75-81. PubMed ID: 2973690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of adjuvant to adaptive immune responses in mice against Actinobacillus pleuropneumoniae.
    San Gil F; Turner B; Walker MJ; Djordjevic SP; Chin JC
    Microbiology (Reading); 1999 Sep; 145 ( Pt 9)():2595-2603. PubMed ID: 10517613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Be Aware of Immunogenic But not Protective Antigens: The Actinobacillus pleuropneumoniae PalA as an Example.
    Liu C; Cao Y; Yang J; Zhao H; Zahid KR; Zhao J; Qi C; Liu J
    Protein Pept Lett; 2017; 24(11):1059-1065. PubMed ID: 28828973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
    Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
    Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA.
    Shin SJ; Bae JL; Cho YW; Lee DY; Kim DH; Yang MS; Jang YS; Yoo HS
    FEMS Immunol Med Microbiol; 2005 Feb; 43(2):155-64. PubMed ID: 15681145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.